Oxcia transforms state-of-art science
into valuable drugs to improve lives

Oxcia AB is a clinical stage life science company with two DNA damage and repair (DDR) drug candidates; Karonudib (MTH1 inhibitor) targeting cancer (Phase 1) and OGG1 inhibitor targeting inflammatory diseases (idiopathic lung fibrosis and NASH, pre-clinical stage).